Treatment strategies for senile dementia: antagonist β-carbolines
An effective pharmacological treatment for senile dementia is not yet available and even the therapeutic potency of muscarinic agonists has been rather disappointing up to now. Different lines of evidence and a hypothesis are presented below suggesting that β-carbolines with antagonist or partial in...
Gespeichert in:
| Veröffentlicht in: | Trends in neurosciences (Regular ed.) 1988, Vol.11 (1), p.13-17 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17 |
|---|---|
| container_issue | 1 |
| container_start_page | 13 |
| container_title | Trends in neurosciences (Regular ed.) |
| container_volume | 11 |
| creator | Sarter, Martin Schneider, Herbert H. Stephens, David N. |
| description | An effective pharmacological treatment for senile dementia is not yet available and even the therapeutic potency of muscarinic agonists has been rather disappointing up to now. Different lines of evidence and a hypothesis are presented below suggesting that β-carbolines with antagonist or partial inverse agonist properties at the GABA-benzodiazepine receptor complex may offer a treatment for senile dementia primarily by disinhibiting the remaining cholinergic neurons of basal forebrain. Preclinical behavioral and biochemical data, as well as studies with human volunteers, support the idea that such β-carbolines exert nootropic effects in general. |
| doi_str_mv | 10.1016/0166-2236(88)90042-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78735452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0166223688900422</els_id><sourcerecordid>78735452</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-7098f4d9ab96dcc60cfab87ac7d8a07a9239f80a206b9b2c936a1951e4abff8a3</originalsourceid><addsrcrecordid>eNp9kM1KxDAQx4Mo67r6Bgo9iR6qSZo2iQdBF79gwcsK3sI0nS6RbrsmWcHX8kF8Jlt38ehhmMP_Y5gfIceMXjDKist-ipTzrDhT6lxTKnjKd8iYKalSRtXrLhn_WfbJQQhvlDKhmBiREReFZkKOye3cI8QltjEJ0UPEhcOQ1J1PArauwaTCQXRwlUAbYdG1LsTk-yu14MuucS2GQ7JXQxPwaLsn5OX-bj59TGfPD0_Tm1lqs1zGVFKtalFpKHVRWVtQW0OpJFhZKaASNM90rShwWpS65FZnBTCdMxRQ1rWCbEJON70r372vMUSzdMFi00CL3ToYqWSWi5z3RrExWt-F4LE2K--W4D8No2ZAZwYuZuBilDK_6MwQO9n2r8slVn-hLatev97o2D_54dCbYB22Fivn0UZTde7_Az84gn7x</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78735452</pqid></control><display><type>article</type><title>Treatment strategies for senile dementia: antagonist β-carbolines</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sarter, Martin ; Schneider, Herbert H. ; Stephens, David N.</creator><creatorcontrib>Sarter, Martin ; Schneider, Herbert H. ; Stephens, David N.</creatorcontrib><description>An effective pharmacological treatment for senile dementia is not yet available and even the therapeutic potency of muscarinic agonists has been rather disappointing up to now. Different lines of evidence and a hypothesis are presented below suggesting that β-carbolines with antagonist or partial inverse agonist properties at the GABA-benzodiazepine receptor complex may offer a treatment for senile dementia primarily by disinhibiting the remaining cholinergic neurons of basal forebrain. Preclinical behavioral and biochemical data, as well as studies with human volunteers, support the idea that such β-carbolines exert nootropic effects in general.</description><identifier>ISSN: 0166-2236</identifier><identifier>EISSN: 1878-108X</identifier><identifier>DOI: 10.1016/0166-2236(88)90042-2</identifier><identifier>PMID: 2469147</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Carbolines - therapeutic use ; Dementia - drug therapy ; Dementia - metabolism ; Humans ; Receptors, GABA-A - drug effects ; Receptors, GABA-A - metabolism</subject><ispartof>Trends in neurosciences (Regular ed.), 1988, Vol.11 (1), p.13-17</ispartof><rights>1988</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-7098f4d9ab96dcc60cfab87ac7d8a07a9239f80a206b9b2c936a1951e4abff8a3</citedby><cites>FETCH-LOGICAL-c357t-7098f4d9ab96dcc60cfab87ac7d8a07a9239f80a206b9b2c936a1951e4abff8a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0166223688900422$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,4009,27902,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2469147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sarter, Martin</creatorcontrib><creatorcontrib>Schneider, Herbert H.</creatorcontrib><creatorcontrib>Stephens, David N.</creatorcontrib><title>Treatment strategies for senile dementia: antagonist β-carbolines</title><title>Trends in neurosciences (Regular ed.)</title><addtitle>Trends Neurosci</addtitle><description>An effective pharmacological treatment for senile dementia is not yet available and even the therapeutic potency of muscarinic agonists has been rather disappointing up to now. Different lines of evidence and a hypothesis are presented below suggesting that β-carbolines with antagonist or partial inverse agonist properties at the GABA-benzodiazepine receptor complex may offer a treatment for senile dementia primarily by disinhibiting the remaining cholinergic neurons of basal forebrain. Preclinical behavioral and biochemical data, as well as studies with human volunteers, support the idea that such β-carbolines exert nootropic effects in general.</description><subject>Animals</subject><subject>Carbolines - therapeutic use</subject><subject>Dementia - drug therapy</subject><subject>Dementia - metabolism</subject><subject>Humans</subject><subject>Receptors, GABA-A - drug effects</subject><subject>Receptors, GABA-A - metabolism</subject><issn>0166-2236</issn><issn>1878-108X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1KxDAQx4Mo67r6Bgo9iR6qSZo2iQdBF79gwcsK3sI0nS6RbrsmWcHX8kF8Jlt38ehhmMP_Y5gfIceMXjDKist-ipTzrDhT6lxTKnjKd8iYKalSRtXrLhn_WfbJQQhvlDKhmBiREReFZkKOye3cI8QltjEJ0UPEhcOQ1J1PArauwaTCQXRwlUAbYdG1LsTk-yu14MuucS2GQ7JXQxPwaLsn5OX-bj59TGfPD0_Tm1lqs1zGVFKtalFpKHVRWVtQW0OpJFhZKaASNM90rShwWpS65FZnBTCdMxRQ1rWCbEJON70r372vMUSzdMFi00CL3ToYqWSWi5z3RrExWt-F4LE2K--W4D8No2ZAZwYuZuBilDK_6MwQO9n2r8slVn-hLatev97o2D_54dCbYB22Fivn0UZTde7_Az84gn7x</recordid><startdate>1988</startdate><enddate>1988</enddate><creator>Sarter, Martin</creator><creator>Schneider, Herbert H.</creator><creator>Stephens, David N.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1988</creationdate><title>Treatment strategies for senile dementia: antagonist β-carbolines</title><author>Sarter, Martin ; Schneider, Herbert H. ; Stephens, David N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-7098f4d9ab96dcc60cfab87ac7d8a07a9239f80a206b9b2c936a1951e4abff8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Animals</topic><topic>Carbolines - therapeutic use</topic><topic>Dementia - drug therapy</topic><topic>Dementia - metabolism</topic><topic>Humans</topic><topic>Receptors, GABA-A - drug effects</topic><topic>Receptors, GABA-A - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarter, Martin</creatorcontrib><creatorcontrib>Schneider, Herbert H.</creatorcontrib><creatorcontrib>Stephens, David N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in neurosciences (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarter, Martin</au><au>Schneider, Herbert H.</au><au>Stephens, David N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment strategies for senile dementia: antagonist β-carbolines</atitle><jtitle>Trends in neurosciences (Regular ed.)</jtitle><addtitle>Trends Neurosci</addtitle><date>1988</date><risdate>1988</risdate><volume>11</volume><issue>1</issue><spage>13</spage><epage>17</epage><pages>13-17</pages><issn>0166-2236</issn><eissn>1878-108X</eissn><abstract>An effective pharmacological treatment for senile dementia is not yet available and even the therapeutic potency of muscarinic agonists has been rather disappointing up to now. Different lines of evidence and a hypothesis are presented below suggesting that β-carbolines with antagonist or partial inverse agonist properties at the GABA-benzodiazepine receptor complex may offer a treatment for senile dementia primarily by disinhibiting the remaining cholinergic neurons of basal forebrain. Preclinical behavioral and biochemical data, as well as studies with human volunteers, support the idea that such β-carbolines exert nootropic effects in general.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>2469147</pmid><doi>10.1016/0166-2236(88)90042-2</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0166-2236 |
| ispartof | Trends in neurosciences (Regular ed.), 1988, Vol.11 (1), p.13-17 |
| issn | 0166-2236 1878-108X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78735452 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Carbolines - therapeutic use Dementia - drug therapy Dementia - metabolism Humans Receptors, GABA-A - drug effects Receptors, GABA-A - metabolism |
| title | Treatment strategies for senile dementia: antagonist β-carbolines |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T11%3A19%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20strategies%20for%20senile%20dementia:%20antagonist%20%CE%B2-carbolines&rft.jtitle=Trends%20in%20neurosciences%20(Regular%20ed.)&rft.au=Sarter,%20Martin&rft.date=1988&rft.volume=11&rft.issue=1&rft.spage=13&rft.epage=17&rft.pages=13-17&rft.issn=0166-2236&rft.eissn=1878-108X&rft_id=info:doi/10.1016/0166-2236(88)90042-2&rft_dat=%3Cproquest_cross%3E78735452%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78735452&rft_id=info:pmid/2469147&rft_els_id=0166223688900422&rfr_iscdi=true |